Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
US-China Talks Target AI, Tariffs Ahead of Trump-Xi Summit 
S&P 500 Historically Rallies After Midterm Elections, UBS Says 
Apple Pay Set for India Launch With Axis Bank 
OpenAI Urges US-Led Global Standards for Frontier AI 
Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
Wall Street Mixed as Treasury Yields Rise After Fed Hike 
Meta Partners With Shopify to Bring Shop Pay Checkout to Muse AI 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Bolivia Approves $1.9 Billion IMF Financing Deal 
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Hyundai CEO Warns Chinese Automakers Could Disrupt US Market 
Add as a preferred source on Google
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
